This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Targeting EGFR Mutation-positive NSCLC: Critical Advances in Care

Targeting EGFR Mutation-positive NSCLC: Critical Advances in Care

Format

Interactive Monograph

Time to Complete

1 hour

Released

September 25, 2018

Expires

September 25, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditsTM

Accredited Provider

Jointly sponsored by The University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning

Commercial Supporter

Supported by an educational grant from Pfizer, Inc.

Program Description

New developments in the role of mutations in the epidermal growth factor receptor (EGFR) gene are transforming the understanding of how non-small cell lung cancer (NSCLC) progresses as a disease. This insight has enabled NSCLC to evolve from an untreatable disease to one where a number of novel therapeutic options are available, and individualized treatment regimens are now offered to optimize care.

This digital flipbook includes pertinent data and video insights into new and practice-changing therapy in the setting of epidermal EGFR mutation-positive NSCLC. Discussion topics include first-line therapy selection, mechanisms of resistance to EGFR tyrosine-kinase inhibitors (TKIs), EGFR TKI therapy beyond progression, and third-generation EGFR TKIs under investigation.

Intended Audience

This is a targeted activity for clinicians to learn about and be updated on new and emerging TKI agents for treatment of NSCLC in the first-, second- and third-line based on the most recent data.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Select personalized first-line therapy for patients with EGFR mutation-positive NSCLC based on clinical factors and molecular subtyping
  • Discuss mechanisms of acquired resistance to EGFR TKI therapy and evidenced-based approaches for selection of sequential therapy in these patients
  • Interpret emerging clinical trial efficacy and safety data that will inform application of EGFR TKIs, including comparator trials, novel agents, and combination regimens

Goals

The goals of this activity are:

  • Clinicians will be better aware, informed and equipped to optimally treat NSCLC patients with mutations in the EGFR tyrosine kinase domain, thus enabling them to achieve better response rates and progression free survival rates
  • Knowledge of the patient populations, clinical trial designs, and efficacy and safety data from available and ongoing trials can facilitate physicians to apply the use of the TKIs in clinical practice
  • Clinicians will be both informed and thus able to make clinical decisions for developing personalized patient treatment regimens from a number of potential therapies for patients with EGFR mutation-positive NSCLC, including combination therapy with checkpoint inhibitors

Conflict Of Interest Disclosure Policy

The Accreditation Council for Continuing Medical Education has announced standards and guidelines to insure that individuals participating in CME activities are aware of program chair(s), planning committee members, faculty/teacher/ authors, CME activity reviewer’s relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.

The University of Texas MD Anderson Cancer Center has, through a formal review process, made every attempt to resolve all potential conflicts of interest prior to this activity. For information on this process, please contact the CME/Conference Management at 713/792-5357.

The following Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.

Faculty

George R. Simon, MD, FACP, FCCP
Professor of Medicine
Department of Thoracic Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Simon discloses the following:
Grant research support: Merck
Paid consultant: Takeda, Merck
Membership on advisory committees: RefleXion, Genprex

H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
Web Editor, JAMA Oncology
Founder & President
GRACE: Global Resource for Advancing Cancer Education
Seattle, WA

Dr. West discloses the following:
Paid consultant: AZ, Genentech.Roche
Speaker’s Bureau: AZ
Membership on advisory committees: Genentech.Roche

Staff Disclosures

The following Faculty/Program Planning Committee Members and CME Activity Reviewers/Approvers HAVE INDICATED THEY HAVE NO FINANCIAL INTERESTS, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financial support this CME activity. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.

Planning Committee Members
George Simon, MD, FACP, FCCP: see disclosure above
Howard (Jack) West, MD: see disclosure above
Angie Castillo
Katlyn Cooper
Arman Nabatiyan, PhD
Greg Paladino

CME Activity Reviewers/Approvers
Diane C. Bodurka, MD, BS, MPH
Larry Driver, MD
David Followill, PhD
Dan Gambos, MD

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL and MD Anderson require the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Instructions

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

If you have any questions relating to the accreditation of this activity, please contact:
Katlyn Cooper
kcooper@achlcme.org

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue